Table 1.
Effects of Se compounds on metastasis (migration, invasion, and angiogenesis).
Se compounds | Studies | Cancer/cells | Function | Reference |
---|---|---|---|---|
MSA | in vitro | HUVEC | reduce MMP-2, apoptosis | [9,30] |
in vitro | human breast cancer cells, MDA-MB-468 and MCF-7 | reduce VEGF | [8] | |
in vitro | human prostate cancer cells, DU145 | reduce VEGF | [8] | |
mice | human prostate cancer cells, DU145 | reduce tumor growth and angiogenesis | [31] | |
rat | rat prostate cancer cells, PAIII | reduce HIF-1α, and VEGF, reduce metastatic lung foci | [32] | |
in vitro | human fibrosarcoma cell, HT1080 | inhibit cell invasion, inhibit MMP-2 activation, reduce MT1-MMP and increase TIMP-2 | [9] | |
mice | Lewis lung carcinoma cell | reduce lung metastasis, reduce plasma uPAand PAI-1 | [33] | |
in vitro | human clear cell renal cell carcinoma, RC2 | reduce HIF-1α, and VEGF | [34] | |
in vitro | human head and neck squamous cell carcinoma, FaDu | reduce HIF-1α, and VEGF, increase prolyl hroxylases | [35] | |
MSC | in vitro | murine breast cancer cells, TM6 | inhibit migration | [36] |
rat | carcinogen-induced breast cancer | reduce angiogenesis | [37] | |
mice | human breast cancer cells, MCF-7 | reduce angiogenesis | [38] | |
mice | human colon cancer cells, HCT-8, HT-29 and GEO | reduce angiogenesis | [39,40] | |
mice | human small cell lung cancer, H69 | reduce microvessel density, increase vascular maturation | [41] | |
mice | human nonsmall epithelial lung carcinimo, A549 | increase vascular maturation | [41] | |
mice | human head and neck squamous cell carcinoma, FaDu | reduce COX-2, iNOS, HIF-1α, and VEGF, reduce microvessel density, increase vascular maturation, drug delivery and distribution | [35,42,43] | |
mice | human head and neck squamous cell carcinoma, A253 | reduce microvessel density, increase vascular maturation, drug delivery and distribution | [41] | |
SeM | mice | murine breast cancer cells, 4T1.2 | most protection against metastasis | [44] |
mice | melanoma | reduce lung metastasis | [45] | |
MeCN | in vitro | HUVEC | reduce MMP-2 | [9] |
methylselenol | in vitro | human fibrosarcoma cell, HT1080 | reduce cell migration and invasion, decrease expression and activity of MMP-2 and MMP-9, increase TIMP1 and TIMP2 | [46] |
selenite | in vitro | HUVEC | apoptosis | [30] |
in vitro | mammaery endothelial cells | reduce VEGF | [47] | |
rat | carcinogen-induced breast cancer | inhibit VEGF, reduce angiogenesis | [37] | |
in vitro | human fibrosarcoma cell, HT1080 | reduce cell migration, reduce cell-ECM attachment, reduce MMP-2, MMP-9 and uPA, increase TIMP-1 | [48] | |
mice | murine melanoma cell, B16BL6 | reduce lung metastasis | [49] | |
mice | murine melanoma cell, B16F10 | reduce lung metastasis | [50] | |
in vitro | murine melanoma cell, B16F10 | inhibit cell migration decrease HIF-1α, VEGF, and IL-18 | [51] | |
rat | carcinogen-indeced liver cancer | reduce angiogenesis, inhibit angiogenic factors | [41] | |
in vitro | human astrocytoma cell, IPSB-18 | reduce MMPs amd EGFR, increase MMP inhibitors | [52] | |
selenate | in vitro | human breast cancer cells, MDA-MB-231 and MCF-7 | enhance epithelial tight junction, inhibit motility and trans-endothelial invasion | [53] |
Se-enriched garlic | rat | carcinogen-induced breast cancer | inhibit VEGF, reduce angiogenesis | [37] |
high Se isolated soy proteins | mice | murine melanoma cell, B16BL6 | reduce lung metastasis | [54] |
Se-enriched malt | rat | carcinogen-indeced liver cancer | reduce angiogenesis, inhibit angiogenic factors | [41,55] |